Clinical trials: Glycemic Control
Type 2 Diabetes
Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
This study evaluates the efficacy and safety of adding the SGLT-2 inhibitor DA5221-T to the combination therapy of DA5221-B1 and the DPP-4 inhibitor DA5221-B2 in patients with type 2 diabetes who have inadequate blood glucose…
- Trial name
- NCT06290349
- Testing
- DA5221-T1, DA5221-T2, DA5221-B1
- Where
- South Korea
- Volunteers
- 174 people
- Sponsor
- Dong-A ST Co., Ltd.
Type 2 Diabetes
Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin
The objective of this study is to evaluate the efficacy and safety of teneligliptin 20 mg orally administered once daily for 24 weeks compared with placebo in patients with type 2 diabetes mellitus who have inadequate glycemic…
- Trial name
- TERA 305 (NCT05504226)
- Testing
- Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet
- Where
- South Korea
- Volunteers
- 214 people
- Sponsor
- Handok Inc.
Type 2 Diabetes
A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus
The purpose of this clinical research study is to learn if BMS-512148 is effective in controlling blood sugar levels as determined by HbA1c and fasting plasma glucose in patients who have been diagnosed with Type 2 diabetes.
- Trial name
- NCT00263276
- Testing
- dapagliflozin, metformin
- Where
- 144 sites in United States, Canada and 2 more
- Volunteers
- 389 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Patients
A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients
PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the safety and tolerability, and pharmacodynamics, of multiple oral doses of PF-04620110 in…
- Trial name
- NCT01298518
- Testing
- PF-04620110
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
A Study to Test MK-0941 in Adults With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0941-018)
The purpose of this study is to test the effect MK-0941 as add-on therapy for adults taking insulin for Type 2 Diabetes.
- Trial name
- NCT00824616
- Testing
- MK-0941, Insulin
- Volunteers
- 68 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients
This study is to evaluate long-term safety and efficacy after concomitant administration of ASP1941 and Nateglinide inhibitor in Japanese patients with type 2 diabetes mellitus.
- Trial name
- NCT01316107
- Testing
- ipragliflozin, nateglinide
- Where
- 4 sites in Japan
- Volunteers
- 122 people
- Sponsor
- Astellas Pharma Inc
Type 2 Diabetes Mellitus
Body Weight Effects on Glucophage's Efficacy in Chinese Diagnosed T2DM Patients
The purpose of this study is to investigate the effect of the baseline body mass index (BMI) on the response to Glucophage XR monotherapy in glycemic control in Chinese patients with newly diagnosed type 2 diabetes
- Trial name
- NCT00778622
- Testing
- Metformin XR
- Where
- 14 sites in China
- Volunteers
- 371 people
- Sponsor
- Bristol-Myers Squibb
Metabolics Diabetes Nos
PPAR-COMBO With Sulfonylurea
A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination with Glyburide Therapy in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate…
- Trial name
- NCT00162175
- Testing
- Muraglitazar
- Where
- 149 sites in United States, Argentina and 13 more
- Volunteers
- 534 people
- Sponsor
- Bristol-Myers Squibb
Diabetes, Diabetes Mellitus, Type 2
Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes
This trial is conducted in the United States of America (USA). The purpose of this study is to test whether Biphasic Insulin Aspart 70/30 twice a day with Metformin improves glycemic control vs.
- Trial name
- NCT00097877
- Testing
- biphasic insulin aspart, insulin glargine
- Where
- 73 sites in United States, Puerto Rico
- Volunteers
- 293 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Transcutaneous Electrical Nerve Stimulator to Improve Blood Glucose Control in Patients With Type 2 Diabetes Mellitus
The primary study objective is to demonstrate the use of "Dragon Waves Resonant Home Care" Electronic Nerve Stimulator (DW1330) is associated with improvement of blood glucose control, as measured by change of glycated hemoglobin…
- Trial name
- NCT03102424
- Testing
- Transcutaneous Electrical Nerve Stimulator (DW1330)
- Where
- 6 sites in Taiwan
- Volunteers
- 160 people
- Sponsor
- Taiwan Resonant Waves Research Corporation
Type 1 Diabetes
The MiniMed™ 780G Glycemic Control and Quality of Life Study for the Treatment of Pediatric and Adult Subjects With Type 1 Diabetes in France.
The purpose of the study is to evaluate the efficacy in glycemic control and the impact on the quality of life of patients using the MiniMed™ 780G System for the treatment of Type 1 diabetes, in real life settings in France.
- Trial name
- NCT04308291
- Testing
- MiniMed™ 780G System
- Where
- 32 sites in France
- Volunteers
- 306 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 2 Diabetes Mellitus (T2DM)
Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM
Study D1690L00149 is a 24-week, multicentre, randomized, parallel, interventional, non-inferiority, open-label study designed to compare the FDC Regimen of Dapagliflozin/Metformin XR with the Dapagliflozin co-administered with…
- Trial name
- NCT06327815
- Testing
- Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets, Dapagliflozin tablets and Metformin HCl extended-release tablets
- Where
- 35 sites in China
- Volunteers
- 633 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone
The purpose of this clinical research study is to learn whether Saxagliptin added to thiazolidinedione (TZD) therapy is more effective than TZD alone as a treatment for Type 2 diabetic subjects who are not sufficiently controlled…
- Trial name
- NCT00295633
- Testing
- Saxagliptin, pioglitazone, rosiglitazone
- Where
- 133 sites in United States, Argentina and 6 more
- Volunteers
- 565 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)
This study will examine the safety and efficacy of the addition of sitagliptin (MK-0431) compared to placebo in patients with type 2 diabetes mellitus with inadequate glycemic control who are taking pioglitazone and metformin.
- Trial name
- NCT00885352
- Testing
- Sitagliptin, Pioglitazone, Metformin
- Volunteers
- 313 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
AVANDAMET Versus Metformin For Type 2 Diabetes Mellitus
This 48-week study will compare AVANDAMET vs. Metformin monotherapy for blood glucose control in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT00241605
- Testing
- rosiglitazone/metformin
- Where
- 91 sites in Canada
- Volunteers
- 600 people
- Sponsor
- GlaxoSmithKline
it is a Group of Metabolic Diseases in, Which a Person Has High Blood Sugar, Either
Effect of Taurine on Glycemic Control in Type I and Type II Diabetic Patients
Diabetes mellitus (DM) and its vascular complications are the one of the most prevalent diseases in the state of Qatar. It is a multifactorial disease associated with the development of retinopathy, nephropathy, neuropathy…
- Conditions
- it is a Group of Metabolic Diseases in, Which a Person Has High Blood Sugar, Either, Because the Body Does Not Produce Enough Insulin,, or Because Cells do Not Respond to the Insulin That
- Trial name
- NCT01226537
- Testing
- Taurine
- Volunteers
- 20 people
- Sponsor
- Hamad Medical Corporation
Improved Glycemic Control in Patients With Type 2 Diabetes
A Trial of HR17031 Injection With Renal Insufficiency
This study used a single-dose, open design to compare the pharmacokinetics of subjects with mild, moderate and severe renal insufficiency and end-stage renal disease and subjects with normal renal function.
- Trial name
- NCT05292495
- Testing
- HR17031 injection
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes
Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin
This study is being carried out to see if Dapagliflozin in addition to insulin is effective and safe in treating patients with type 2 diabetes when compared to placebo (identical looking inactive treatment) in addition to insulin
- Trial name
- NCT00673231
- Testing
- Dapagliflozin
- Where
- 92 sites in United States, Austria and 11 more
- Volunteers
- 1,240 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
This is a study to evaluate the efficacy and safety of ertugliflozin (MK-8835/PF-04971729) in combination with sitagliptin in the treatment of participants with Type 2 diabetes mellitus (T2DM) with inadequate glycemic control on…
- Trial name
- NCT02226003
- Testing
- Ertugliflozin, Sitagliptin, Glimepiride
- Volunteers
- 291 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin
The purpose of this study is to compare the effects of saxagliptin with those of placebo as add-on therapy to insulin and insulin with metformin in improving glycemic control at 24 and 52 weeks.
- Trial name
- NCT00757588
- Testing
- Saxagliptin, 5 mg + insulin
- Where
- 80 sites in United States, Canada and 8 more
- Volunteers
- 455 people
- Sponsor
- AstraZeneca